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List of abbreviations 
ACTH: adrenocorticotropic hormone 
ANCOVA: analysis of covariance 
BDI: Beck Depression Inventory 
BMI: body mass index 
CD: Cushing’s disease 
EPQ-RK: Eysenck Personality Questionnaire 
FBeK: Fragebogen zur Beurteilung des eigenen Körpers 
FKB-20: Fragebogen zum Körperbild 
FSH: follicle-stimulating hormone 
GH: growth hormone 
HDL: high-density lipoprotein 
LDL: low-density lipoprotein 
LH: luteinizing hormone 
MIDAS: Migraine Disability Assessment 
MRI: magnetic resonance imaging 
NFPA: non-functioning pituitary adenomas 
QoL: Quality of Life 
TPQ: Cloninger Temperament and Personality Questionnaire 
TSH: thyroid-stimulating hormone 
TSS: transsphenoidal surgery  
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Introduction 
Hormonal excess syndromes due to pituitary adenomas are rather rare, though various 
studies suggest that their prevalence might in some cases be 3.5 – 5 times higher than 
previously reported (Daly et al., 2006). Clinical presentation of pituitary adenomas is 
broad and can be divided into symptoms resulting from the change in endocrine status 
such as hormonal excess depending on the hormone produced or pituitary insufficiency 
and into symptoms resulting from the pituitary mass per se. 
Patients with hormonal excess syndromes present with a variety of cardiovascular 
comorbidities depending on the hormone overproduced. Uncontrolled acromegaly is 
associated to increased morbidity and mortality, mainly due to cardiovascular 
comorbidities such as arterial hypertension, cardiomyopathy, heart valve disease, 
arrhythmias, atherosclerosis, coronary artery disease and cardiac dysfunction (Colao et 
al. 2008; Fedrizzi et al. 2008). These are supposed to be normalized or at least partially 
reversed after biochemical control is achieved (Melmed 2009). Cushing’s disease (CD) 
is also associated to increased morbidity and mortality, mostly due to cardiometabolic 
comorbidities such as arterial hypertension, glucose intolerance, diabetes mellitus, 
dyslipidaemia, thromboembolic complications as well as a hypercoagulable state 
(Mancini et al., 2004; Pivonello et al., 2005; Boscaro et al., 2002). Transsphenoidal 
surgery (TSS) presents the treatment of choice for CD (Biller et al., 2008); remission 
rates following TSS are dependent on tumor size and extension, adenoma visibility on 
preoperative magnetic resonance imaging (MRI) as well as neurosurgical expertise and 
recurrence is frequent (Tritos et al., 2011). Treatment for hypercortisolism has been 
associated with a significant reduction in mortality and morbidity. However, even after 
long-term cure of the disease, patients exhibit a persistent unfavorable cardiometabolic 
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risk profile as in active hypercortisolemia (Faggiano et al., 2003; Barahona et al., 
2009). 
It is also increasingly recognized that patients with hormonal excesses suffer from 
neuropsychiatric side-effects, not only due to the neuroanatomic position of the 
pituitary mass itself. A few years ago, a high variability of emotional problems was 
detected in patients with different types of pituitary adenomas (Flitsch et al. 2000). 
Moreover, it is known that patients with pituitary adenomas frequently suffer from pain 
syndromes e.g. headache (Levy et al. 2005; Kreitschmann-Andermahr et al. 2013). 
Previous work from our group could show that acromegaly, a state of growth-hormone 
excess, is associated with an increased prevalence of affective disorders, anxiety-related 
personality traits, disturbances of the macroscopic brain tissue architecture and 
cognitive dysfunction (Sievers et al. 2009; Sievers et al. 2012).CD reflects chronic 
cortisol excess and also comprises a broad spectrum of psychiatric manifestations 
(Pereira et al., 2012), which do not necessarily correlate with the degree of 
hypercortisolism and often remain despite biochemical remission of the disease. 
Chronic exposure to elevated glucocorticoid levels has been suggested to lead to 
deficits in cognitive function and short-term memory as well as brain morphology 
changes (Bourdeau et al., 2002; Forget et al., 2002) and altered personality (Sonino et 
al., 2006). Impaired quality of life (QoL) in active CD is a consistent finding in many 
different studies having implications for the long-term management of the disease 
(Lindsay et al. 2006; Feelders et al. 2012). 
Although the association between cardiovascular and neuropsychiatric comorbidities 
and pituitary disease is well established, to our knowledge only a few studies have 
investigated systematically and with standardised instruments cardiovascular and 
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especially neuropsychiatric aspects such as psychopathology, neuropsychology, 
personality, sleep, pain, brain architecture and quality of life in patients with hormonal 
excess syndromes and how these comorbidities and symptoms are affected by different 
therapy regimens. 
 
Objectives 
First aim of the work present herein was to investigate the clinical characteristics of 
pain in a large cohort of patients with pituitary disease, since clinical presentation of 
pituitary adenomas frequently involves pain due to structural and functional properties 
of the tumor. Growth hormone and IGF-1 play an important role in the regulation of 
metabolism and body composition. Subsequently, we went on to examine body 
composition and cardiovascular risk profile in a subgroup of patients with pituitary 
disease, patients with controlled acromegaly. In an attempt to investigate why diagnosis 
of acromegaly is delayed up to 10 years after disease onset despite obvious 
external/objective changes, we hypothesized that a lack of subjective perception of the 
disease state, possibly mediated by psychiatric or cognitive alterations, might contribute 
to the delayed initiation of a diagnostic work-up. 
Patients with a different kind of pituitary adenoma, Cushing’s disease, have been of 
particular interest within this project. In order to be able to look into long-term 
remission and recurrence rates of transsphenoidal surgery, the treatment of choice for 
CD, it was further necessary to conduct a retrospective analysis in a series incorporating 
different neurosurgeons in the Munich Metropolitan Region. In a parallel approach, we 
went on to investigate personality in patients with CD, since chronic hypercortisolism 
has been suggested to contribute to an altered personality profile in these patients.  
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Studies carried out and main findings 
1. Pain in Patients with Pituitary adenomas 
Dimopoulou C, Athanasoulia AP, Hanisch E, Held S, Sprenger T, Toelle TR, 
Roemmler-Zehrer J, Schopohl J, Stalla GK, Sievers C. The clinical characteristics of 
pain in patients with pituitary adenomas. Eur J Endocrinol. 2014 Aug 12. [Epub ahead 
of print] 
Aim of this study was to describe the clinical characteristics of pain in patients with 
pituitary adenomas such as acromegaly, Cushing’s disease (CD), prolactinomas and 
non-functioning pituitary adenomas (NFPA). We evaluated primary site of perceived 
pain, quality of pain, nociceptive vs neuropathic pain components, side shift, 
severity/intensity, frequency and duration, associated symptoms, trigger factors, family 
history in relation to pain as well as pain alleviating factors in patients with pituitary 
adenomas and how these might be influenced by modifiable factors such as tumor and 
treatment characteristics. The role of pain on disability and QoL was also assessed. 
Table 1: Demographic, tumor and treatment characteristics as well as comorbidities of the 
overall study population and according to each tumor subtype. Adapted from Dimopoulou et 
al., 2014. 
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The most common pain location for the whole group was the lower back (67%), 
followed by the neck (66%) and the shoulder/arm/hand region (66%). No pain side shift 
was reported by the majority of the pituitary adenoma patients (91%). The commonest 
quality of pain was described as “deep” (n=180; 65%). 62% of acromegaly, 80% of 
CD, 64% of prolactinoma and 58% of NFPA patients (p>0.05) reported “deep” pain. 
Pituitary adenoma patients reported on a scale of 0 (=no pain) to 10 (=most severe pain) 
a mean pain intensity of 4±2, the most severe pain intensity as 6±2 and the mildest pain 
intensity as 2±2within the last 4 weeks. CD patients reported the most severe pain 
intensity with 7±2, whereas prolactinoma patients reported the mildest pain intensity 
with 2±2. The majority of the study population (41%) complained of episodic pain, 
while 21% complained of permanent pain. CD patients were most frequently affected 
by permanent pain (31%). Chronic pain with pain attacks accounted only for 10% of 
patients. Median pain duration was 14±10 years. 
Table 2: Pain side shift, quality, intensity and frequency amongst tumor subtypes. Adapted 
from Dimopoulou et al., 2014. 
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Visual disturbances (28%), noise sensitivity (19%), nausea (19%) and photophobia 
(18%) were the commonest pain associated symptoms. Pain was accompanied by visual 
disturbances in 25%, 27% and 28% of the acromegaly, prolactinoma and NFPA 
patients, respectively, whereas CD patients most frequently associated pain to 
photophobia (29%). Pain appeared to be triggered in 41% of the pituitary adenoma 
patients by physical stress, followed by emotional stress (21%) and other causes (16%). 
"Resting" (44%) and the use of motion/exercise (25%) comprised non-pharmacological 
alleviating factors. No family history of pain was recorded in the majority of the 
pituitary adenoma patients (86%) (acromegaly 83%; CD 84%; prolactinoma 84%, 
NFPA 93%) (p>0.05). 
Table 3: Pain associated features, trigger factors, alleviating factors and family history within 
the study population. Adapted from Dimopoulou et al., 2014. 
The majority of the patients (72%) suffered from little or no headache-related disability 
(Grade I) on daily life, according to MIDAS. 73% of the acromegalic, 63% of the CD, 
72% of the prolactinoma and 70% of the NFPA subjects had little or no headache-
related disability within the subgroups. 25% of the CD population reported severe 
headache-related disability (Grade IV) though. 
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Figure 1: Distribution of Migraine Disability Assessment (MIDAS) scores amongst tumor 
types and for the group as whole. Adapted from Dimopoulou et al., 2014. 
The highest MIDAS scores were recorded in the CD and NFPA patient group (20±40 
and 12±38, respectively). The mean MIDAS score for the whole group was 12±33 days. 
Screening criteria for a nociceptive pain component were fulfilled in the majority of the 
patients (80%), followed by uncertain pain (11%) and a neuropathic pain component 
(1%). 84% of the acromegalic, 78% of the CD, 72% of the prolactinoma and 88% of 
the NFPA subjects complained of nociceptive pain within the subgroups(figure 2). 
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Figure 2: Distribution of painDETECT scores amongst tumor and for the group as whole. 
Adapted from Dimopoulou et al., 2014. 
The highest mean painDETECT scores were seen in the prolactinoma and CD patient 
group (9±8 and 8±7, respectively). Mean painDETECT score for the whole group was 
7±7. 
There was significant difference regarding the pain DETECT score (p=0.007) between 
patients with hormonal hypersecretion independent of tumor type and patients with 
biochemically controlled pituitary disease. Modifiable factors such as tumor size, 
genetic predisposition, previous surgery, irradiation or medical therapy did not show 
significant impact on headache-related disability (MIDAS score) or neuropathic pain 
components (painDETECT score). 
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Table 4: Pearson’s r correlation coefficients between neuropathic pain components 
(painDETECT) and headache-related disability (MIDAS) with depression (BDI) and health-
related quality of life (visual analogue scale EQ-VAS) in all 278 patients and within the 
subgroups. . Adapted from Dimopoulou et al., 2014. 
All correlations between neuropathic pain, depression and impaired health-related 
quality of life showed statistical significance in (p<0.05). As far as headache-related 
disability was concerned, there was again statistical significance in nearly all 
correlations with depression except for acromegalic (p=0.412) and prolactinoma 
patients (p=0.315), as well as with health-related quality of life except for NFPA 
patients (p=0.127). 
Taken together, these data demonstrate that: (i) bodily pain is highly prevalent in 
patients with pituitary adenomas independent of the tumor type; (ii) compared to other 
patient groups, CD patients are especially susceptible to pain; iii) most pituitary patients 
suffer from nociceptive pain; (iv) a high incidence of headache was recorded 
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independent of tumor type; however, the majority of the study population reported little 
or no headache-related disability in everyday life; (v) modifiable factors such as tumor 
size, genetic predisposition, previous surgery, irradiation or medical therapy do not 
seem to have a significant impact on pain; (vi) there is significant correlation between 
pain and pain-related disability with depression and impaired QoL. 
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2. Cardiovascular risk profile in Patients with Acromegaly 
Dimopoulou C*, Sievers C*, Wittchen HU, Pieper L, Klotsche J, Roemmler J, 
Schopohl J, Schneider HJ, Stalla GK. * both authors contributed equally. Adverse 
anthropometric risk profile in biochemically controlled acromegalic patients: 
comparison with an age- and gender-matched primary care population. Pituitary. 2010 
Feb 4. [Epub ahead of print] 
Aim of this study was to evaluate the cardiovascular risk profile of “biochemically 
controlled” acromegalic patients by comparing their anthropometric parameters and 
cardiovascular risk biomarkers to an age- and gender-matched primary care control 
group. We performed stratified analyses in diabetic and non-diabetic patients 
separately, since acromegaly is associated with an increased risk of diabetes mellitus, 
which might influence the calculations. 
Anthropometric parameters, such as weight, BMI, waist and hip circumference 
(86.6±17.8 vs. 79.8±17.4 kg; p=0.002; 29.2±5.2 vs. 27.5±5.6 kg/m2; p=0.014; 
100.0±14.3 vs. 95.7±15.5 cm; p=0.026; 110.6±9.2 vs. 105.6±12.0 cm; p=0.001, 
respectively) were significantly higher in the whole group of acromegalic patients in 
comparison to their respective controls. Cardiovascular risk biomarkers such as fasting 
plasma glucose, total cholesterol, triglycerides and HDL levels were more favorable in 
the acromegalic group compared to the age- and gender-matched controls, interestingly. 
As far as comorbidities were concerned, acromegalic patients suffered significantly 
more often from hypertension (54.3 vs. 37.8 %; p=0.008) and malignancies (11.1 vs. 
3.1 %; p=0.005), but less often from myocardial infarction (1.2 vs. 36.7%; p=0.001), 
compared to their controls. 
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Table 5: Comparisons of comorbidities, anthropometric parameters and cardiovascular risk 
biomarkers between patients with acromegaly (n=81) and the age- and gender-matched 
DETECT-controls (n=320). Adapted from Dimopoulou et al., 2010. 
The study group was further stratified into controlled and uncontrolled patients and 
compared to their respective primary care control patients. 
Anthropometric measurements such as weight (85,6±17.9 vs. 78.5±18.5 kg; p=0.015), 
BMI (29.5±5.9 vs. 27.3±5.8 kg/m2; p=0.020), waist (100.9±16.8 vs. 94.8±15.5 cm; 
p=0.031) and hip circumference (110.7±9.9 vs. 105.0±11.7 cm; p=0.001) were 
significantly higher in biochemically controlled patients in comparison to their 
respective DETECT controls. On the other hand, cardiovascular risk biomarkers, such 
as fasting plasma glucose (90.9±16.7 vs. 104.8±39.3 mg/dL; p=0.000) and triglycerides 
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(118.5±59.4 vs.153.8±123.1 mg/dL; p=0.006), were significantly lower in 
biochemically controlled patients. We performed the same analyses excluding patients 
who had been irradiated or were pituitary-deficient, since radiation might be also 
involved in the genesis of pituitary deficiency with effects on both body composition 
and cardiovascular risk biomarkers. Similar results with significant differences in BMI, 
waist and hip circumference between the groups (p=0,039, 0,015 and 0,001, 
respectively) were observed (table 6). 
Table 6: Comparisons of comorbidities, anthropometric parameters and cardiovascular risk 
biomarkers between biochemically controlled (n=49) and uncontrolled patients (n=31) and the 
age- and gender-matched DETECT-controls (n=196 and n=120, respectively). Adapted from 
Dimopoulou et al., 2010. 
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We carried out further stratified analyses with acromegalic patients and primary care 
controls with and without type 2 diabetes mellitus, in order to exclude type 2 diabetes 
mellitus as a potential confounder for our calculations. Twenty-two acromegalic 
subjects were diagnosed with diabetes mellitus (age- and gender-matched control group 
of patients with diabetes mellitus n=88) during the course of the disease or treatment. 
Table 7: Comparisons of comorbidities, anthropometric parameters and cardiovascular risk 
biomarkers between acromegalic patients with (n=22) and without diabetes mellitus (n=59) and 
the age- and gender-matched DETECT-controls (n=88 and n=232, respectively). Adapted from 
Dimopoulou et al., 2010. 
We did not detect any significant differences in anthropometric parameters between 
acromegalic patients with diabetes mellitus and controls with diabetes mellitus, as 
presented in table 7. Acromegalic patients with diabetes mellitus even showed an 
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improved cardiovascular risk profile regarding HDL (61.7±20.8 vs. 53.3±16.5 mg/dL; 
p=0.010) and lipoprotein (a) levels (13.8±8.5 vs. 37.6±54.7 mg/dL; p=0.021), but not 
regarding total cholesterol, triglycerides and LDL. Acromegalic patients without 
diabetes mellitus had significantly more often hypertension (49.2 vs. 37.9%; p=0.007), 
but lower fasting plasma glucose (89.9±11.9 vs. 104.3±36.8 mg/dL; p=0.011), total 
cholesterol (214.3 ±39.0 vs. 227.1 ±45.9 mg/dL; p=0.031) and triglycerides’ levels 
(107.1 ±54.4 vs. 158.8 ±128.2 mg/dL; p=0.000), compared to their respective controls. 
Taken together, this study demonstrates that biochemically controlled acromegalic 
patients exhibit an adverse anthropometric risk profile compared to an age- and gender-
matched primary care control cohort. 
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3. Body image in Patients with Acromegaly 
Dimopoulou C, Leistner SM, Ising M, Schneider HJ, Schopohl J, Rutz S, Kosilek R, 
Frohner R, Stalla GK, Sievers C. Body Image Perception in Acromegaly is Not 
Associated with Objective Acromegalic Changes, But Depends on Depressive 
Symptoms. Neuroendocrinology. 2016 Jul 25. [Epub ahead of print] 
Aim of this study was to investigate whether acromegalic patients show altered body 
image perception compared to a clinical control group of patients with non-functioning 
pituitary adenomas (NFPA) who lack any physical/bodily changes. The underlying 
hypothesis was that acromegalic patients might only show mildly altered body image 
perception despite marked objective changes. Delayed disease diagnosis might be due 
to this inability to recognize objective physical changes. Additionally, we analyzed 
associations for impaired body image with other potentially causal factors e.g. objective 
acromegalic changes as judged by medical experts, psychiatric pathology such as 
depression and cognitive impairment, time of hormonal excess and treatment status. 
Acromegalic men had significantly higher mean values in the negative body image 
scale (22.5±6.3 vs. 18±4.6; p< 0.001), whereas both acromegalic men and women 
scored significantly lower in the vital body dynamics scale (31.3±7.9 vs. 38±4.2; p< 
0.001 for men and 27.4±7.8 vs. 37 ±5.8; p< 0.001 for women) of the FKB-20 
questionnaire, compared to normative values. 
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Table 8: Clinical characteristics of the study population. Adapted from Dimopoulou et al., 
2016. 
Further, acromegalic patients (both men and women) suffered from an unfavorable 
body image, showing significantly higher mean values in 2 of the 3 FBeK scales (p< 
0.001 for insecurity/paresthesia and p< 0.001 for accentuation of the body) compared 
to normative values. It was of interest that acromegalic women scored significantly 
higher in the attraction/self-confidence scale (17.6 ±2.3 vs. 9 ±3.1; p< 0.001). 
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Figure 3: Comparisons between patients with acromegaly, patients with NFPA and norm 
values of students in FBeK-scales. Adapted from Dimopoulou et al., 2016. 
There was significant difference between acromegalic and NFPA patients only in the 
vital body dynamics scale of the FKB-20 questionnaire (F = 5.040, p = 0.003), whereby 
NFPA women showed the lowest (24.8±6.3) and NFPA men the highest scores 
(31.6±6.7). There were no significant differences between acromegalic and NFPA 
patients (both groups divided into men and women) in any of the three FbeK subscales. 
Figure 4: Comparisons between patients with acromegaly, patients with NFPA and norm 
values of students in FKB-20-scales. Adapted from Dimopoulou et al., 2016. 
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Further, we associated impaired body image in acromegalic patients with other 
potentially causal factors. Regarding the FKB-20, we tested differences in body image 
for patients without depression (BDI < 10), patients with mild or moderate depression 
(10≤ BDI < 18) and patients with clinical depression as indicated by BDI equal or larger 
than 18. As expected, patients with clinical depression (BDI ≥ 18) scored significantly 
lower in vital body dynamics (F = 29.967, p < 0.001) and significantly higher in 
negative body image (F = 20.293, p < 0.001), according to the FKB-20 (figure 5). 
 
 
 
 
Figure 5: Differences between patients without 
depression, with mild or moderate depression 
and with clinical depression in FKB-20-scales. 
Adapted from Dimopoulou et al., 2016. 
 
We went on to test whether cognitive decline might be responsible for disturbed body 
image and analyzed differences in body image perception between acromegalic patients 
with cognitive impairment – defined as a percentile ranking of lower than 16 – and 
those with normal cognitive status; we did not detect any significant differences 
between the two groups. 
In a subgroup of acromegalic patients with available frontal and side photographs of 
the faces (n=39), patients were grouped into subjects with mild (n=14), moderate 
(n=19), and severe acromegaly (n=6) by expert opinion and we tested whether different 
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degrees of severity might lead to different body image. No significant correlations 
between visual disease severity and unfavorable body image were found (table 9). 
Table 9: Disease severity and body image perception. Adapted from Dimopoulou et al., 2016. 
Further analysis associating disturbed body image with modifiable factors such as time 
of hormonal excess or satisfactory treatment status according to laboratory values did 
not detect any significant correlations with any scale of the body image questionnaires. 
Taken together, this study demonstrates that body image perception in patients with 
acromegaly does not differ from patients with NFPA, although these patients do not 
exhibit physical/bodily changes. This lack of bodily self-perception correlates to the 
presence of depression, though was not different between patients with different disease 
severity, different duration of hormonal excess or biochemical control of the disease. 
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4. Outcomes of Transsphenoidal surgery for Cushing's disease 
Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M, 
Stalla GK. Long-term remission and recurrence rates after first and second 
transsphenoidal surgery for Cushing's disease: Care reality in the Munich Metropolitan 
Region. Eur J Endocrinol. 2013 Nov 11. [Epub ahead of print] 
Aim of our study was to assess in the long-term remission and recurrence rates of CD 
after 1st and after 2ndtranssphenoidal surgery (TSS) in the Munich Metropolitan Region, 
which is accommodated by three major tertiary university neurosurgical centers and 
multiple, smaller neurosurgical centers, reflecting care reality in this region. Our 
hypothesis was that remission rates might be lower and recurrence rates might be higher 
in our series comprising different neurosurgeons, when compared to remission and 
recurrence rates published from single-surgeon expert neurosurgical series. 
Additionally, we focused on the role of 2nd TSS in the current therapeutic regimen for 
CD, correlated postoperative hypocortisolism and risk of recurrence and described our 
therapeutic strategy in patients with persistent disease after TSS. 
Table 10: Neurosurgical centers, where 1st and 2nd TSS were performed. Adapted from 
Dimopoulou et al., 2013. 
 
 
 
 
 
 
 
 
 
 
Table 11: Baseline characteristics of the study 
population. Adapted from Dimopoulou et al., 
2013. 
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Following primary surgery, the overall remission rate was 71% (n=120). A remission 
rate of 79% was accomplished in the microadenoma group (n=58), while in the 
macroadenoma group (n=32), remission rate after first TSS was 69%. In cases of no 
visible adenoma (n=30), remission rate was 57% (table 12). Mean follow-up after first 
TSS was 79±67 (range 252) months. After successful first TSS, overall recurrence rate 
was 34% (22% of patients with microadenoma, 59% of patients with macroadenoma 
and 35% of patients with no visible adenoma; p=0.007). Time to recurrence after first 
TSS ranged from 5 to 205 months (mean of 54±54 months). 
Second TSS was considered in all cases of persistent or recurrent CD after first TSS 
(n=64), according to the current treatment algorithm for CD. Second TSS (n=28) was 
not performed in patients with ACTH-secreting macroadenomas with tumor invasion 
into the cavernous sinus or sphenoid (n=8), who might not benefit from a second 
operation, in case of patients’ unwillingness to undergo second TSS (n=12) or other 
contraindications to surgery (n=8). Thirty-six of 120 CD patients (30%) underwent 
second TSS. Second TSS was carried out by the same surgeon, in the same 
neurosurgical center where first TSS took place in 64 % (23/36), suggesting patients’ 
satisfaction. Overall remission rate of CD after second TSS was 42% (36% of patients 
with microadenoma, 29% of patients with macroadenoma and 75% of patients with no 
visible adenoma). Mean follow-up after second TSS was 62±54 (range 187) months. 
Overall recurrence rate after successful second TSS was 40% (40% of patients with 
microadenoma, 75% of patients with macroadenoma and 17% of patients with no 
visible adenoma). The time to recurrence after second TSS was shorter (mean 27±29, 
range 3 - 76 months). 
 
26 
 
Table 12: Remission rates, disease persistence, recurrence rates and mean time to recurrence 
after first TSS, after second TSS and at final follow-up according to preoperative MRI. Adapted 
from Dimopoulou et al., 2013. 
 
Figure 6: Kaplan–Meier curve showing freedom from recurrence of Cushing's disease in 
patients after successful first and/or second TSS. Adapted from Dimopoulou et al., 2013. 
Within this study, 30 patients with no visible tumor on preoperative MRI underwent 
TSS; during surgery a pituitary adenoma was detected in 16/30 cases (53%). A 
systematic dissection of the pituitary gland was performed in the remaining cases 
(n=14); only one patient underwent total hypophysectomy. Of the 8 patients with no 
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visible tumor preoperatively, a pituitary adenoma was visualised during second TSS in 
2/8 cases (25%). The remaining 6 patients received a systematic dissection of the 
pituitary gland; one patient received a hemi-hypophysectomy. In the cases where no 
definite tumor was not found during surgery, remission rates after first and second TSS 
were 50% and 100%, respectively. 
There were no significant differences in remission and recurrence rates after first and 
after second TSS when comparing outcomes of each participating center (table 13). 
Table 13: Remission rates, disease persistence and recurrence rates after first and after second 
TSS according to neurosurgical center. Adapted from Dimopoulou et al., 2013. 
Postoperative hypocortisolism was diagnosed in all patients on biochemical testing 
while in hospital (serum cortisol <5ug/dL). 65/120 CD patients (54%) presented with 
postoperative hypocortisolism after first TSS (64% in the microadenoma group, 47% 
in the macroadenoma group and 43% in the group of no visible adenoma) (mean 
duration 45±60, range 252 months). Patients with postoperative hypocortisolism 
following first TSS were 0.7 times less likely to suffer disease recurrence than patients 
with postoperative eucortisolism (risk = 0.72; 95% confidence interval (CI) 0.60 – 0.88; 
Exact Sig. (2-sided) p=0.035). Longer duration of postoperative hypocortisolism did 
not prevent from CD recurrence (48±64. vs. 32±22 months; p=0.186). Overall 
frequency of postoperative hypocortisolism after second TSSwas 33% (12/36 patients) 
(36% in the microadenoma group, 29% in the macroadenoma group and 63% in the 
group of no visible adenoma) (mean duration 15±16, range 56 months). Postoperative 
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hypocortisolism after second TSS (risk = 0.83; 95% CI 0.25 – 2.73; Exact Sig. (2-sided) 
p=1.000), nor its longer duration (17±17 vs. 5 months; p=0.55) prevented patients from 
disease recurrence. 
Of the 120 CD patients included in this analysis, 92% were in remission at final follow-
up (100% in the group of no visible adenoma, 97% in the microadenoma and 75% in 
the macroadenoma group). Overall, 8% of the CD patients suffered from disease 
persistence at final follow-up (table 12). Nine patients were lost to follow up (n=8 after 
1st TSS, n=1 after 2nd TSS). 
Regarding pituitary deficiencies, 81 of 120 (68%) patients presented with deficiency of 
at least one pituitary hormone at final follow-up, with ACTH being influenced in most 
cases with 51% (isolated ACTH deficiency in 29%). Frequencies of LH/FSH, TSH and 
GH deficiencies accounted for 29%, 22% and 22%, respectively. Posterior pituitary 
deficiency was less frequent (8%). 
Taken together, remission rates after first TSS in our series incorporating different 
neurosurgeons were comparable with available literature, whereas recurrence rates both 
after first and second TSS fell at the higher end of the published single-surgeon series 
so far, supporting our study hypothesis. Second TSS was responsible for long-term 
remission in additional 8% of the CD patients. Postoperative hypocortisolism after first 
TSS, though not its duration, was associated with a lower risk of CD recurrence. At 
final follow-up, hypopituitarism of any degree persisted in some patients. 
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5. Personality in Patients with Cushing's Disease 
Dimopoulou C, Ising M, Pfister H, Schopohl J, Stalla GK, Sievers C. Increased 
Prevalence of Anxiety Associated Personality Traits in Patients with Cushing's Disease: 
A Cross-Sectional Study. Neuroendocrinology. 2012 Apr 28. [Epub ahead of print] 
 
Aim of this study was to verify the hypothesis that patients with CD show an anxiety-
associated personality profile as well as to determine the effects of disease- and 
treatment-related factors that might contribute to these personality traits. We employed 
two standardized personality questionnaires, the Cloninger Personality Questionnaire 
(TPQ) and the short version of the revised Eysenck Personality Questionnaire-RK 
(EPQ-RK), in order to test this hypothesis. Additionally, we contrasted CD patients 
against a clinical control group with NFPA and age- and gender-matched mentally 
healthy controls to exclude the possibility that pituitary adenomas and/or their treatment 
are associated with anxiety associated personality traits. 
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Table 14: Demographic and clinical characteristics of the study groups. Adapted from 
Dimopoulou et al., 2012. 
Patients with CD showed significantly less novelty seeking behaviour (TPQ-NS; 
p<0.001), which comprises low exploratory excitability (TPQ-NS1; p<0.001) and low 
extravagance (TPQ-NS3; p=0.015), compared to mentally healthy controls. Moreover, 
CD patients reported more anticipatory worries and pessimism (TPQ-HA1; p<0.001), 
higher fear of uncertainty (TPQ-HA2; p<0.001), shyness with strangers (TPQ-HA3; 
p<0.001), fatigability and asthenia (TPQ-HA4; p<0.001), indicating high harm 
avoidance (TPQ-HA; p<0.001). Overall, CD patients were not more reward dependent 
(TPQ-RD; p>0.05). We could not detect any significant differences between the two 
groups regarding sentimentality, persistence, attachment or dependence. As far as the 
three personality dimensions defined by Eysenck are concerned, CD patients were more 
neurotic (EPQ-N; p<0.001) and socially desirable (EPQ-SD; p=0.040), but less 
extraverted (EPQ-E; p=0.003), compared to a mentally healthy population. 
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We also documented elevated scores in harm avoidance (TPQ-HA; p<0.001), social 
desirability (EPQ-SD; p<0.001) and neuroticism (EPQ-N; p<0.001) in NFPA patients 
in comparison to mentally healthy controls. Results for novelty seeking (TPQ-NS) and 
extraversion (EPQ-E) were similar, whereas CD patients showed reduced scores on 
these scales when compared with mentally healthy controls. The highest scores 
regarding neuroticism (EPQ-N) were recorded in CD patients, followed by significantly 
lower scores in NFPA patients (p=0.003), which were still higher than those detected 
in mentally healthy controls (p<0.001). 
Table 15: Personality traits of the study groups. Adapted from Dimopoulou et al., 2012. 
Additionally, we applied ANCOVA controlling for age and gender, in order to assess 
personality differences between biochemically controlled and uncontrolled CD 
patients, between hypopituitary patients vs. patients with normal pituitary function, 
between radiated vs. non-radiated CD patients or dependent on disease duration 
(>median vs. <median). Moreover, we carried out a subgroup analysis in patients with 
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and without arthralgia, since chronic pain might be altering personality. Persistent 
hypercortisolemia was associated with significantly higher fear of uncertainty (TPQ-
HA2; p=0.008), fatigability and asthenia (TPQ-HA4; p=0.034), indicating overall high 
harm avoidance (TPQ-HA; p=0.036) when contrasted to biochemically controlled CD. 
Besides, patients with hypopituitarism were more shy with strangers (TPQ-HA3; 
p=0.011) in comparison to patients with normal pituitary function. 
In conclusion, a distinct pattern of personality traits associated with high anxiety in 
combination with traits of low externalizing behaviour is present in CD patients. This 
personality profile is comparable with acromegalic patients, but only partly with NFPA 
patients. Persistent hypercortisolemia and hypopituitarism, though not radiation therapy 
or duration of active hypercortisolism were partially associated with these personality 
traits. The reported personality pattern might constitute an additional challenge for 
diagnosis and therapy of CD and might contribute to impaired social and psychological 
functioning and well-being. 
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Discussion 
The studies presented herein had as initiating point the need to further elucidate 
cardiometabolic and neuropsychiatric risk profile in patients with pituitary adenomas 
even after long-term biochemical control of the disease. 
Regarding pain syndromes, a high prevalence of bodily pain and headache was 
documented in patients with pituitary adenomas (Dimopoulou et al. 2014). Although 
the causal connection between bodily pain and pituitary disease is not clear, we know 
e.g. that persistent GH excess in acromegaly can lead to arthropathy and arthralgia 
(Biermasz et al., 2005). The fact that CD patients are more susceptible to developing 
pain (Dimopoulou et al. 2014) is not surprising, since hypothalamo-pituitary-adrenal 
axis dysfunction has been suggested as a contributing factor to the development of 
chronic pain both in animal models and in clinical studies (Alexander et al., 2009). 
Modifiable factors such as tumor size, genetic predisposition, previous surgery, 
irradiation or medical therapy did not have significant influence neither on neuropathic 
pain nor on headache-related disability (Dimopoulou et al. 2014), which rather suggests 
previous irreversible effects on the central nervous system leading to chronic pain. 
One should also bear in mind that patients with pituitary adenomas not only suffer from 
pain syndromes, but additionally show decreased quality of life and sleep as well as 
increased rates of depression compared with matched controls. A significant proportion 
of the reduced quality of life can be attributed to the presence of depression and worse 
sleep quality (Leistner et al. 2015). These findings are comparable with previous results 
about QoL in patients with pituitary adenomas (van der Klaauw et al., 2008), as well 
as with results about subjective sleep quality of separate patient groups e.g. of 
acromegaly (Copinschi et al., 2010) or NFPAs (Biermasz et al., 2010). 
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The involvement of growth hormone and IGF-1 in the regulation of metabolism and 
body composition is well known. In a cross-sectional study, biochemically controlled 
patients with acromegaly were shown to have an adverse anthropometric risk profile, 
mainly due to elevated adiposity measurements (Dimopoulou et al. 2010). According 
to the literature, these findings can be attributed to a number of factors: Relative 
“overtreatment of acromegaly” might be resulting in relative growth hormone 
deficiency. Schmid et al. 2006 have proposed other pituitary deficiencies as the 
underlying cause for an adverse anthropometric risk profile in acromegaly. 
Additionally, acromegalic patients are known to lack physical exercise because of 
persisting joint complaints or arthropathy (Biermasz et al. 2005), while medical 
treatment for acromegaly itself might also be responsible for increased measurements 
of body mass and body fat (Plöckinger et al., 2008). 
Despite obvious external changes, diagnosis of acromegaly is often delayed long after 
disease onset. This hypothesis was, however, not confirmed by our findings, since body 
image perception of acromegalic patients did not differ from NFPA controls, who do 
not show physical/bodily changes. This lack of bodily self-perception was similar in 
patients with different disease severity, different duration of hormonal excess or 
biochemical control, but correlated to depression (Dimopoulou et al., 2016). These 
findings are in accordance with previous studies reporting disturbed body image in 
acromegalic patients (Ezzat, 1992; Pantanett et al., 2002). These results also 
correspond to our previous work, showing that patients with acromegaly burden high 
neuropsychiatric morbidity including high prevalence of affective disorders (Sievers et 
al., 2009), macroscopic brain architecture changes (Sievers & Samann et al., 2009), 
anxiety-related personality traits (Sievers et al., 2009), cognitive dysfunction (Sievers 
et al., 2012) and pain syndromes (Dimopoulou et al., 2014). Tiemensma et al. have also 
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documented affected illness perceptions in acromegalic patients even after long-term 
remission of the disease (Tiemensma et al., 2011) and recently, increased psychosocial 
impairment has been linked to diagnostic delay in acromegaly (Siegel et al., 2013). 
However, emotional disorders do not seem to burden only acromegalic patients, but 
also patients with other types of pituitary adenomas, affecting the diagnostic process, 
as seen in our NFPA controls (Flitsch et al., 2000). 
Furthermore, we showed that except for traditional remission criteria for acromegaly 
such as biochemical variables, modifiable factors e.g. depression and anxiety are 
superior over biochemical control in predicting quality of life and might provide 
valuable targets for possible future treatment interventions (Geraedts et al. 2015). 
TSS presents the treatment of choice for CD, caused by an ACTH-secreting pituitary 
adenoma. Remission and recurrence rates are dependent on tumor size, extension, 
adenoma visibility on MRI and neurosurgical expertise. In our series incorporating 
different neurosurgeons in the Munich Metropolitan Region, we reported - against our 
study hypothesis - an overall remission rate of 71% after first TSS, comparing 
favourably with the literature (Tritos et al., 2011). The high disease persistence as well 
as high recurrence rates identified both after first and after second TSS, might be 
attributed to the fact that our endocrinology departments serve as referral centers for 
difficult, complicated cases. Postoperative hypocortisolism following first TSS was 
associated with a lower risk of suffering disease recurrence, as has been shown in the 
literature by Patil et al. 2008. Second TSS, which should be considered in patients with 
refractory or recurrent CD, led an additional 8% of the patients to long-term CD 
remission; at this point, we have to take into account that we reported not on a single-, 
but on a multiple-surgeon series involving different neurosurgical skills and reflecting 
care reality in the Munich Metropolitan Region (Dimopoulou et al. 2013). 
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Chronic hypercortisolism has been suggested to contribute to an altered personality 
profile in patients with CD. In our series, CD patients were characterized by elevated 
anxiety-related personality traits, harm avoidance and neuroticism, combined with 
reduced scores in externalizing traits, novelty seeking and extraversion. This pattern 
has been previously recorded by our group in acromegaly (Sievers et al., 2009), while 
NFPA patients serving as clinical control group described themselves by lower - though 
still elevated - neuroticism scores. Our results were comparable with the findings by 
Tiemensma et al., 2010, who documented “maladaptive” traits even after long-term 
cure of CD. In agreement with these findings, we observed elevated scores in anxiety-
related traits as well as reduced scores in externalizing traits, which corresponds to 
higher scores on social avoidance as reported by Tiemensma et al., 2010. Persistent 
cortisol excess correlated - as expected - with anxiety-related personality traits 
including higher scores on harm avoidance in total, but also on the subscales fear of 
uncertainty and fatigability and asthenia (Dimopoulou et al. 2013). 
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Summary and Conclusions 
Summarizing, the studies described herein have contributed to understanding that 
patients with hormonal excess syndromes show a persistent unfavorable 
cardiometabolic and neuropsychiatric risk profile even after long-term biochemical 
control of the disease. Impaired quality of life persists as a remaining effect of long-
standing hormonal excess. Despite advanced neurosurgical expertise and evoking 
therapy regimens over the years, hormonal excess syndromes represent due to high 
recurrence and persistence rates an ongoing challenge for the treating physicians/ 
endocrinologists and require complex interdisciplinary approach and multimodal 
treatment strategies to be able to treat these patients properly. Our findings suggest that 
neuropsychiatric assessment should be integrated in the diagnostic and therapeutic 
work-up of patients with hormonal excess syndromes in order to treat them 
appropriately and improve their quality of life. Neuropsychiatric changes should be 
taken into account when treating such patients, as they might interfere with the patient-
physician communication and/or challenge the patients' social and psychological 
functioning. Due to the lack of large patient cohorts with available biomaterial, 
structured patient registries and consultation hours are needed in order to develop 
personalized therapy strategies for these patients. Additionally, randomized studies 
with a prospective design are necessary to be able to draw conclusions between the 
causal relationship of hormonal excess syndromes and associated changes and the 
development of a cardiovascular and neuropsychiatric risk profile. 
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